查詢結果分析
相關文獻
- A Follow-up Study of Systemic-Onset Juvenile Rheumatoid Arthritis in Children
- Lowered IL-4-producing T Cells and Decreased IL-4 Secretion in Peripheral Blood from Subjects with Juvenile Rheumatoid Arthritis
- Long-Term Effects of Azathioprine Therapy for Juvenile Rheumatoid Arthritis
- Sulfasalazine Therapy for Juvenile Rheumatoid Arthritis
- Efficacy and Safety of Methotrexate Therapy for Juvenile Rheumatoid Arthritis
- Etanercept Therapy in Children with Juvenile Rheumatoid Arthritis
- Treatment with Etanercept for Patients with Juvenile Rheumatoid Arthritis in Taiwan--A Preliminary Report
- Taiwan Experience with Etanercept in Juvenile Rheumatoid Arthritis
- Different Familial Association Patterns of Autoimmune Diseases between Juvenile-onset Systemic Lupus Erythematosus and Juvenile Rheumatoid Arthritis
- 讓孩子自由自在的活動--幼年型類風濕性關節炎治療的新趨勢
頁籤選單縮合
題 名 | Long-Term Effects of Azathioprine Therapy for Juvenile Rheumatoid Arthritis=Azathioprine 治療幼年型類風濕性關節炎之長期效果 |
---|---|
作 者 | 林于粲; 楊曜旭; 蔡銘哲; 江伯倫; | 書刊名 | 臺灣醫學會雜誌 |
卷 期 | 99:4 2000.04[民89.04] |
頁 次 | 頁330-335 |
分類號 | 418.2133 |
關鍵詞 | 幼年型類風濕性關節炎; Azathioprine; Juvenile rheumatoid arthritis; Efficacy; Side-effects; |
語 文 | 英文(English) |
英文摘要 | Background and purpose: Juvenile rheumatoid arthritis (JRA) can result in disability, growth disturbance, and systemic complications. This study investigated the efficacy and adverse effects of azathioprine (AZA) therapy in children with JRA. Methods: Data from the medical records of 24 children with JRA treated with oral AZA during the period from 1988 to 1998 were retrospectively analyzed. All 24 patients had received two or more nonsteroidal anti-inflammatory drugs (NSAIDs) and 12 had received disease-modifying antirheumatic drugs (DMARDs) prior to the start of AZA. Of the 24 patients, 21 were corticosteroid-dependent prior to the onset of AZA therapy. The indication for AZA therapy was lack of efficacy of the current treatment regimen. The initial and maximal doses of AZA averaged 1.7 mg kg –1 ·d – 1 (range, 1–3 mgkg –1 ·d –1 ) and 1.9 mg kg –1 ·d –1 (range, 1–6 mg kg –1 ·d –1 ), respectively. The mean duration of treatment was 13 months (range, 4–37 mo). The mean duration of follow-up was 45 months (range, 7–137 mo) from the start of AZA therapy. Results: Fifteen children (62.5%) showed clinical improvement, while the other nine (37.5%) achieved clinical remission. AZA treatment resulted in a more than 50% reduction in the required corticosteroid dose in seven children and complete discontinuation of corticosteroid administration in eight children. None of the patients treated with AZA doses of 1 to 3 mgkg –1 ·d –1 developed AZA-related side-effects. Two patients suffered from AZA-related adverse effects due to AZA overdose (6 mg kg –1 ·d –1 ). Both experienced pancytopenia and disseminated infection, which resolved following reduction of the AZA dose to 3 mg kg –1 ·d –1 . Conclusions: AZA is an effective and well-tolerated steroid-sparing agent for JRA refractory to NSAIDs or DMARDs. |
本系統中英文摘要資訊取自各篇刊載內容。